a. Conference on Integrative and Personalized Medicine and 42" Annual Conference of Indian Pharmacological Society Ce Z = & December 10-12, 2009 Swabhuni, Kolkata Spanning genes, bench and bedside Jointly organized by National Research Institute of Ayurveda for Drug Development and Indian Pharmacological Society, West Bengal Branch IPSCON-2009 Secretariat Office of the Director National Research Institute of Ayurveda for Drug Development 4.CN Block, Sector V, Salt Lake, Kolkata -700 091 E-mail: info@ipscon2009.0rg va srt e| vs ateAbstracts” “ater of * tet tree oaps (0° group) were use for prog experince ‘86 of Sagar, glaucoma enplning1OP RECOVERY MODEL. After recrting baseline OR hypertonic saline (109% sodium chore solution) was infused. ~ * through tbe marginal ear vein for te all of1OP The recovery of OF after tara ale: lcm ca cer) be they A spar chura in (O5N) ant passin cane peer RD) Le sronea a Y Methods Avoattar tes gun, was sel 20 nes trae eae ee Aa oes amie ir Steen ts a ah # entroate ann. esayie The eats towed ut the nt peup en Teak Aan clophosphamide (roan POs uproar ee shes dsr Ses cach Acehnese hans deseo ce sod sigtcnt P<0.05) grupsia 72, TSan 71 eq Ra TOR oun 120 5.34 mms ean SEN ne ent (gpa station ofa sane nou wey wna Sasene Pas dee 240 = 6: mimic = Sa ‘fon 22" day) of group I indicated. {nstilation of diltiazem whereas in group 3, recovery to mean baseline nia as record to normal YP oud cheater Le 1002 3h mos Conclusions: The findings suggest that potassium channel openers ‘have potential to increase 10F,s0 must be carefully administered othe Patients who ave potential to develop glauooma, where a calcum ‘@ic reaction in ‘anne! blockers have 10P lowering elec. and they canbe ulized as 3 Potential investigative antiglaucoma drs. ee 1SV, Barhate SD! Singhal axe PP-038 ‘LS. S. Patil Coltege of Quality and content assessment of two batches of ‘ashira “University of Saga, ‘Tour marketed Brahmi formulations. Saini N, Agrawal SS, Mathur Delhi Institute of Pharmaceutical Science and Research (DIPSAR), es of Stopaladi Chuma were Delhi, India, Systemic anaphylactic E-mail: mathurrajani@yahoo.com mice. Mortality eacllonwas Objectives: Qualtative assessment of two batches each of four Ke) orally commercial formulations of Brahmi (S61, SH2; Hl, H2: SI, $2: Mi, 48/80. The ‘M2) procured from local market and check inter-batch variation in was also {the content of Bacoside A. Methods: As per the method in Ayurvedic mpound — Pharmacopeia of India, the formulations were assessed in terms of © while specifications oftabel, uniformity of weight of capsules total ash, acid -P.0.) insoluble ash, water soluble extractives, alcohol soluble extractives tmid Joss on drying. Bacoside A was quantified in each sample Using ‘Uv-spectrophotometer. Results: Variations in label claim in terms Of type of extract, extraction ratios, content were recorded. In SB1 ‘and $B2, 2 and 30 capsules Were counted in botles, respectively, Instead of 60, as per label claim. S1,S2,M2 failed uniformity of weight f content SB1 and 2, M2.H1, $1 and 2 failed loss on drying: M1 and 2, S1 and 2 failed total ash content; H2, M2, S2, SB2 failed acid ash content; H2, M1 and 2 failed alcohol soluble extractive. goside A content of hydrolyzed extract was estimated He), H2 (4.3%), Ml (1.75%), M2 (13.68%), St (11.9%), $B1 (31.65%) and SB2 (26.4%) w/w. Conclusion: atch-to-botch variation inthe marketed Brom ‘Quality standards of herbal formulations needs to y checked in accordance with the standard guidelines e activity of fruit-pulp of